- Home
- GOSS vs ZTR Comparison
GOSS vs ZTR Comparison
Compare GOSS & ZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- ZTR
- Stock Information
- Founded
- GOSS 2015
- ZTR 1988
- Country
- GOSS United States
- ZTR Australia
- Employees
- GOSS N/A
- ZTR N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- ZTR Investment Managers
- Sector
- GOSS Health Care
- ZTR Finance
- Exchange
- GOSS Nasdaq
- ZTR Nasdaq
- Market Cap
- GOSS 347.8M
- ZTR 349.4M
- IPO Year
- GOSS 2019
- ZTR N/A
- Fundamental
- Price
- GOSS $2.47
- ZTR $6.37
- Analyst Decision
- GOSS Strong Buy
- ZTR
- Analyst Count
- GOSS 4
- ZTR 0
- Target Price
- GOSS $8.50
- ZTR N/A
- AVG Volume (30 Days)
- GOSS 3.1M
- ZTR 219.4K
- Earning Date
- GOSS 08-05-2025
- ZTR 01-01-0001
- Dividend Yield
- GOSS N/A
- ZTR 12.09%
- EPS Growth
- GOSS N/A
- ZTR N/A
- EPS
- GOSS N/A
- ZTR N/A
- Revenue
- GOSS $40,237,000.00
- ZTR N/A
- Revenue This Year
- GOSS N/A
- ZTR N/A
- Revenue Next Year
- GOSS $30.65
- ZTR N/A
- P/E Ratio
- GOSS N/A
- ZTR N/A
- Revenue Growth
- GOSS N/A
- ZTR N/A
- 52 Week Low
- GOSS $0.66
- ZTR $4.50
- 52 Week High
- GOSS $2.65
- ZTR $6.60
- Technical
- Relative Strength Index (RSI)
- GOSS 68.08
- ZTR 64.07
- Support Level
- GOSS $2.38
- ZTR $6.27
- Resistance Level
- GOSS $2.65
- ZTR $6.35
- Average True Range (ATR)
- GOSS 0.15
- ZTR 0.04
- MACD
- GOSS 0.03
- ZTR 0.01
- Stochastic Oscillator
- GOSS 76.67
- ZTR 85.06
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About ZTR Virtus Total Return Fund Inc.
Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective of capital appreciation, with current income as a secondary objective. The Fund seeks to meet its objectives through a balance of equity and fixed income investments.